Culture

Predicting success in therapy with individualized cancer models

image: Cell Surface Stem Cell Marker (green), dividing cells (red) and DNA (blue).

Image: 
Marianna Kruithof-de Julio and Marta De Menna

In the EU alone, 78,800 men died of prostate cancer last year. While tumors discovered at an early stage can often be completely removed by surgery and radiation therapy, the prospects of successful treatment are reduced if the cancer has further metastasized. At present, physicians cannot predict drug response or therapy resistance in patients.

Three-dimensional structures

The team led by PD Dr. Marianna Kruithof-de Julio at the Urology Research Laboratory at the Department for BioMedical Research (DBMR) of the University of Bern and Inselspital Bern, has developed a new strategy for the generation of prostate cancer organoids that can contribute to assess therapy response, their work is published in the latest issue of Nature Communications. Drs Sofia Karkampouna and Federico La Manna, the two lead co-authors of the paper, spent over one and a half year in optimizing and efficient protocol for the generation of the patient derived organoids and their detailed characterization. Moreover, in collaboration with the NEXUS Personalized Health Technologies, they have meticulously developed a medium-throughput screen for drug testing.

The researchers led by PD Dr. Kruithof-de Julio have demonstrated that patient-derived organoids retain relevant characteristics of the prostate carcinoma from which they have been originated: not only are they characterized by the same genetic mutations, but they also exhibit similar gene activity patterns.

Paving the way for personalized medicine

PD Dr. Kruithof-de Julio and her collaborators first generated a novel early stage, patient derived xenograft that is treatment naïve, then tested 74 different drugs on organoids from this and other experimental tumor models - identifying 13 compounds that reduced prostate cancer cell viability.

The researchers then tested the efficacy of these compounds on organoids from five prostate cancer patients - two with early-stage tumors and three with advanced metastatic tumors. Interestingly, among the hits ponatinib, so far approved for the treatment of leukemia, proved to be particularly effective in reduction of organoid viability and tumor growth in vivo.

However, for PD Dr. Kruithof-de Julio, the significance of these results lies not only in the drug repurposing but more importantly in promoting an approach that the medical community can undertake. "Our results pave the way for personalized medicine. In our study we only analyzed data from five patients retrospectively," says Kruithof-de Julio. "But we clearly showed that the method would be in principle feasible. Growing the organoids and drug testing can be accomplished in two weeks, a time frame that is compatible with clinical decision making. In collaboration with the Urology Department of the Inselspital, led by Prof Thalmann, we have now already been able to prove this in several cases."

"In my clinical activity, I am regularly confronted by tumors that do not respond to therapy or for which we do not know which therapy to use", says Thalmann. "This is a further step in the direction of individualized medicine, where we might be able to tailor the treatment to the tumor during the course of the disease and better understand its biology." With this approach, the researchers hope to treat patients more efficiently with less side effects and diminished costs.

Credit: 
University of Bern

Tocilizumab cuts mortality risk in severely ill COVID-19 patients finds new trial conducted in India

Tocilizumab, an anti-inflammatory drug used to treat rheumatoid arthritis, improves outcomes in severely ill COVID-19 patients, finds the results of a new trial conducted in hospitals across India -- one of the world's most ethnically diverse countries. Researchers from the University of Bristol and Medanta Institute of Education and Research in India who led the study, published in The Lancet Respiratory Medicine, say it adds to existing evidence supporting the drug's use in critically ill patients.

Conducted in 12 public and private hospitals across India, the COVID India Tocilizumab (COVINTOC) phase 3 randomised controlled trial aimed to investigate whether tocilizumab could prevent disease progression and mortality in hospitalised patients with moderate to severe COVID-19.

The study team recruited 180 patients (age 18-years and over) who had been hospitalised with moderate to severe COVID-19. Of these, 89 patients were randomised to receive standard care, and 91 patients were randomised to receive standard care plus tocilizumab.

Patients were followed up over a 28-day period to record any clinical improvement markers and assess disease progression from moderate to severe or from severe to death. The team also recorded whether patients experienced adverse events, serious adverse events, and post-treatment infections, and requirement for renal replacement drugs.

Analysis of the data revealed a subset of patients with severe disease in whom tocilizumab might have a reduced risk for progression to death if treated with tocilizumab in addition to standard care. However, clinical parameters or biomarkers to reliably identify these patients and the optimal timing of treatment during COVID-19 progression remain unknown. The authors conclude that while the study does not support the routine use of tocilizumab in adults with COVID-19 it adds to the growing evidence suggesting it may help some severely ill patients.

The trial's co-author, Professor A. V. Ramanan from the University of Bristol's School of Clinical Sciences, and Consultant Paediatric Rheumatologist at Bristol Royal Hospital for Children, said: "Our study suggests tocilizumab might still be effective in patients with severe COVID-19 and so should be investigated further in future studies. It adds to existing evidence from the RECOVERY and REMAP-CAP studies which demonstrate that tocilizumab does have a significant impact on reducing mortality in those with COVID-19 requiring oxygen or being ventilated.

"After dexamethasone (steroids), this is still the most significant advance in the treatment of COVID that has an impact in reducing deaths."

Lead Dr Arvinder Soin, Chairman of the Medanta Liver Transplantation Institute at Gurugram, India, said: "While there were no differences in mortality and the need for ventilation among the two groups of patients when moderate and severe categories of patients were considered together, a subgroup analysis of the severe patients in the two groups showed a lower mortality at 28 days (8/50; 16 per cent) among those who received tocilizumab compared to those who did not (14/41; 34 per cent). The reported adverse events did not differ between the tocilizumab and standard care arms.

"Given the conflicting results of the previous studies, millions were wasted last year on the indiscriminate use of tocilizumab, as the precise stage of the disease in which to use the drug was not clear. This study plugs an important gap in knowledge on COVID treatment and clarifies that tocilizumab should be administered to patients in the severe category. Incidentally, last month, two major studies from the UK - the RECOVERY Trial and the REMAP-CAP study - have revealed similar findings, that tocilizumab reduces mortality among patients with severe COVID-19."

The trial was conducted against incredible odds across multiple sites under difficult conditions in a country that has the second highest COVID-19 caseload in the world.

Professor Ramanan added: "Challenges to conducting randomised controlled trials during the COVID-19 pandemic are exacerbated in low-and middle-income countries, and several hurdles were encountered during this trial in India. Patients treated with drugs not licenced for the condition they have or compassionate use of treatments in patients with COVID-19 is common and can impede enrolment into clinical trials. Ensuring follow-up is challenging for patients who are likely to be discharged early because of the high demand on hospital resources and for patients who might have logistical difficulty travelling for return visits. We believe it is important that all potential therapies be trialled across diverse settings, not only in North America and Europe."

Credit: 
University of Bristol

BU researchers identify basic mechanisms that regulate HIV expression

(Boston)--Despite the positive advances that anti-human immunodeficiency virus (HIV) therapy, commonly called anti-retroviral therapy (ART) or highly active antiretroviral therapy (HAART), has had on the life expectancy of HIV-positive people, finding a cure for HIV or acquired immunodeficiency syndrome (AIDS) has remained elusive.

"One of the major challenges in curing HIV is that there is a persistent latent reservoir of virus that is not targeted by current antiretroviral treatments and is hidden from immune cells. When treatment is interrupted, this reservoir of the virus allows the HIV to rapidly rebound," explained corresponding author Andrew J. Henderson, PhD, professor of medicine and microbiology at Boston University School of Medicine.

In an effort to identify cellular pathways that influence the establishment, maintenance and reversal of HIV persistence, the researchers conducted studies with yeast to screen a large library of human factors for binding to HIV deoxyribonucleic acid (DNA) sequences responsible for virus' expression. As a result, they identified several factors as potential regulators and confirmed that a subset of factors did control HIV in infected cells by increasing and decreasing levels of HIV expression.

"Our study identified novel transcription factors that influence HIV and provide an appreciation into cellular networks that influence activation and repression of different HIV strains," said Henderson.

According to the researchers, understanding the mechanisms that control HIV expression will provide insight into HIV replication, latency and pathogenesis. "By gaining an understanding of the cellular pathways that control HIV, we might be able to target them and alter the behavior of this latent reservoir," Henderson added.

Credit: 
Boston University School of Medicine

COVID-19: Biomarkers linked to severe forms of the disease

A team of researchers from the CHUM Research Centre has identified new biomarkers associated with the severity of COVID-19 in infected patients.

Recent scientific literature has shown that the immune response plays a central part in the severity of COVID-19 disease. Understanding the immune responses generated during the course of the disease is therefore essential to determine which patients are at highest risk for serious complications and death from the disease.

In a new study published in the Journal of Clinical Investigation, scientists and clinicians led by Dr.?Catherine Larochelle, researcher at the CHUM Research Centre, have shown that a set of immune alterations are specifically linked to infection with the SARS-CoV-2 virus, as well as to the severity of COVID-19 disease, its 30-day evolution, and its 60-day mortality. These biomarkers could represent potential therapeutic targets.

We have discussed this with Dr. Larochelle, Professor at the Université de Montréal (Department of Neuroscience) and principal author of the study.

Q. Your experimental approach is rather unique. Based on the immune profiling you conducted, how were you able to identify the patients most at risk for a poor prognosis?

Above all, this is the result of a tremendous collective effort by several dozen people involved in research and clinical work at the CHUM, who participated in this study and in the Quebec?COVID-19 (BQC19) Biobank.

Based on a blood test, we were able to inventory the immune cell populations present in 50 patients with SARS-CoV-2 and compare them to those of 22 patients (of similar gender and age) hospitalized for other acute illnesses, and those of 49 healthy controls.

This immune profiling allowed us to identify subsets of "dysregulated" immune cells specific to patients affected by SARS-CoV-2. Most notably, some of these immune alterations were associated with ventilation needs and mortality in these same patients.

These markers specific to SARS-CoV-2 could then help us to identify the patients at greatest risk, and suggest new avenues for developing therapeutic targets.

In addition, we confirm what has been observed in other studies: disturbances in the immune system such as neutrophilia or lymphopenia, for example, are related to the severity of the disease in hospitalized patients, but are not specific to SARS-CoV-2.

From a clinical perspective, this could explain why general anti-inflammatory treatments such as steroids seem to work in COVID-19 and other acute diseases.

Q. How do you see your results being used directly in a clinical setting? Is it technically feasible?

These assays could be easily transferred to clinical settings, because we worked with very small amounts of blood--less than one millilitre--to develop these immune profiles.

In our experimental approach, we used techniques commonly employed in hospital laboratories: use of surface antibodies to "stain" the cells that express certain markers, flow cytometry (cell characterization and counts), etc. In a clinical setting, this could help track the progress of patients over time and ultimately identify those at high risk who would require closer monitoring.

Q. What therapeutic horizons do you envision for your research work?

I hope that our study will lead to the development of biomarkers that will help us stratify patients based on their risk of developing a severe form of the disease. This should also allow us to identify new therapeutic targets, and to better select those patients who might benefit from certain available therapeutic approaches.

Credit: 
University of Montreal Hospital Research Centre (CRCHUM)

Hybrid microbes: Genome transfer between different bacteria strains explored

Bacteria integrate genetic material from other bacterial strains more easily than previously thought, which can lead to improved fitness and accelerated evolution. This is shown in a recent study by biophysicists at the University of Cologne. The team analysed genome transfer between bacteria of different lineages. The study was published in the journal PNAS.

In the experiment, the team brought one strain of bacteria into contact with DNA fragments from another strain. The uptake of foreign genetic material is known as horizontal gene transfer -- in contrast to vertical gene transfer, by which genes are inherited from a parent cell of the same lineage. The results show that laboratory evolution through horizontal gene transfer can rapidly produce hybrid organisms of different lineages with extensive genomic and functional changes. "It is a bit like interbreeding modern humans and Neandertals'", says Dr. Fernanda Pinheiro of the Institute of Biological Physics at the University of Cologne and author of the study. The bacteria readily integrated foreign DNA at many sites in the genome. Within 200 generations, the research team observed the exchange of up to 14 percent of the bacterium's core genes.

Horizontal gene transfer is an important factor in bacterial evolution that can operate across species boundaries. "Yet we know little about the rate and genomic targets of cross-strain gene transfer. Also, little is known so far about the effects on the physiology and fitness of the recipient organism", says Pinheiro. From a scientific perspective, hybrid creatures whose parents belong to different species raise fundamental evolutionary biology questions: What combinations of traits yield viable organisms? What are the limits of evolutionary processes when more than one species is involved in reproduction? "Our study makes an important contribution here," Pinheiro adds.

Is the uptake of genes random or does it follow a definite pattern? As the researchers observed, some functional units of the foreign genome were repeatedly imported and the resulting hybrid bacteria had higher growth rates. "This implies that cross-lineage gene exchange drives evolution very efficiently," Pinheiro says. Integrating foreign genes through horizontal gene transfer produces new combinations of genes yet preserves essential structures that make a cell viable. Thus, the study opens new perspectives for future work: to combine transfer evolution experiments and synthetic biology methods to engineer functional innovations.

Credit: 
University of Cologne

Hospital-based violence intervention program engages vulnerable populations

image: A retrospective cohort study of violent penetrating injury in Boston 2013-2018.

Image: 
KIRSTY CHALLEN, B.SC., MBCHB, MRES, PH.D., LANCASHIRE TEACHING HOSPITALS, UNITED KINGDOM.

DES PLAINES, IL - A Boston violence intervention advocacy program is effectively engaging the client population that hospital-based violence intervention programs (HVIPs) have been designed to support. This is the conclusion of a study titled Boston Violence Intervention Advocacy Program: Challenges and Opportunities for Client Engagement and Goal Achievement, to be published in the March 2021 issue of Academic Emergency Medicine (AEM), a journal of the Society for Academic Emergency Medicine (SAEM).

According to the study, HVIPs should consider which types of client needs prove most challenging to address and which novel strategies will engage vulnerable populations not typically targeted by intervention programs. These results speak to the difficulties of program attrition and the complexities of altering the life course for victims of violence.

The lead author of the study is Elizabeth C. Pino, PhD, from the Department of Emergency Medicine and the Boston Violence Intervention Program at Boston Medical Center.

Commenting on the study is Tolulope Sonuyi, MD, an emergency medicine physician and assistant professor for the Detroit Medical Center and Wayne State University, respectively, who specializes in health-centered intervention and prevention strategies around community violence.

"With the increased cognizance of the impact that social determinants of health (SDOH) have on the health of emergency department patients, this is a timely study that nicely demonstrates the influence that critical SDOH domains play in the role of the chronic recurrent disease process of community violence. Furthermore, this study provides a framework to understand the impact that patient characteristics have on the uptake of therapeutic intervention and highlights the challenges that come with addressing the upstream factors of complex biopsychosocial disease processes such as community violence. This is important in informing efforts on a systemic and structural level so that more targeted, efficient, and customized strategies may be considered."

Credit: 
Society for Academic Emergency Medicine

No more sitting in the dark?

(COLUMBUS, Ohio) - Concussion, a form of traumatic brain injury, is a common injury among children and teens. Concussions can have adverse effects on physical, cognitive, emotional and sleep health. Clinical guidelines for managing concussion in children and teens traditionally recommend complete physical and cognitive rest until symptom resolution, followed by a gradual return to activities like school and sports. These guidelines are often disputed and based on expert consensus as opposed to strong evidence. The challenge has been how to quantify the amount of physical and cognitive activity that children and teens should engage in during recovery. A new study by researchers at the Center for Injury Research and Policy, Sports Medicine, and Emergency Medicine at Nationwide Children's Hospital investigated objectively measured, self-paced physical and cognitive activity across the first week post-concussion.

The study, published today in the Journal of Head Trauma Rehabilitation, found that self-paced physical and cognitive activity during the first week after sustaining a concussion alone neither hastened nor prolonged concussion recovery in children and teens. These findings indicate that children and teens with concussion may have some flexibility to determine their own activity levels during recovery. Physicians may encourage safe, non-contact, light physical activity if it does not make youths' concussion symptoms worse, while also continuing to emphasize appropriate amounts of necessary rest.

Study participants were 11 to 17 years old, seen within 72 hours of injury in the emergency department or a concussion clinic through Nationwide Children's Hospital and received a physician-confirmed diagnosis of concussion. They wore two devices - one to measure their physical activity and sleep around the clock, and one to measure their cognitive activity outside of school. Participants rated their daily concussion symptoms by completing the Postconcussion Symptom Scale during the first week post-injury.

Researchers found that while daily physical and cognitive activity increased across the first week post-injury, daily post-concussion symptoms decreased. Increased daily step count was associated with an increased likelihood of early symptom resolution. However, this association was not statistically significant after adjusting for acute post-concussion symptoms and other covariates.

"This study is the first to objectively measure self-paced cognitive activity during the first week post-injury," said Ginger Yang, PhD, MPH, lead author of the study and principal investigator in the Center for Injury Research and Policy at Nationwide Children's. "While increased physical and cognitive activity may help reduce post-concussion symptoms, reduced symptoms may also lead to increased physical and cognitive activity levels, highlighting the need for further research to better understand this bi-directional relationship." Such research will provide evidence of when an individual is ready for physical and cognitive activity after concussion and what level of activity is most appropriate. This information could be used by clinicians to inform treatment decisions, including individualized physical and cognitive activity recommendations post-concussion.

"Concussions behave somewhat like snowflakes in that they are not all the same, and the specific effects of concussion on our young patients varies greatly - one size or treatment does not, necessarily, fit all," said Thomas Pommering, DO, co-author of the study and division chief of sports medicine at Nationwide Children's. "The strength of this study is that it appears that children and adolescents with concussions are generally pretty good at self-pacing their physical and cognitive activity so as to not prolong their recovery. With the guidance of physicians, there may be room for personalized treatment plans based on the symptom burden, while still following important guidelines protecting the patient from repeat head injury during the recovery time."

Data for this study came from youth-parent dyads referred to the study team by their school athletic trainer or recruited at the Nationwide Children's Hospital emergency department or concussion clinics. Following a physician-confirmed diagnosis of concussion, youth-parent dyads were contacted by research staff and enrolled within 72 hours post-injury after providing written assent and consent. Enrolled dyads were then followed until symptom resolution (defined as being symptom-free or symptoms returned to pre-injury level), or 45 days post-injury, whichever occurred first.

Credit: 
Nationwide Children's Hospital

Latest research delineates the effectiveness of "quitlines" for smoking cessation

While cigarette smoking continues to be the leading cause of preventable disease, disability and death in the U.S., the evidence base for cessation support has revealed that telephone call centers, or "quitlines," have been a particularly successful intervention, according to the Centers for Disease Control and Prevention (CDC), which recently published a compilation of scientific research in the American Journal of Preventive Medicine.

Titled "The Role of Quitlines in Tobacco Cessation," the supplement is composed of nine peer-reviewed articles and three commentaries presenting the latest science on quitlines' effectiveness for smoking termination. The compilation demonstrates the relevance and importance of call centers as an essential population-level tool designed to increase successful smoking suspension outcomes, and their role as part of a comprehensive approach to tobacco control. Furthermore, it points to shifts in the commercial tobacco product landscape that will require the ongoing improvement and innovation in quitlines' technology to continue to effectively support smokers who want to quit to successfully cease.

According to the CDC, nearly 500,000 U.S. adults die prematurely of smoking tobacco or exposure to second-hand smoke, while over 16 million live with a serious illness caused by smoking each year. Additionally, smoking-related disease among adults costs the U.S. over $300 billion annually, including $170 billion in direct medical care and $150 billion in lost productivity due to premature death.

While cigarette smoking has significantly decreased among U.S. adults since the 1960s, 14 percent were still smokers in 2019, and its prevalence remains high among individuals who are less educated, low-income, LGBT, of a certain race and ethnicity, and people with behavioral health concerns.

"The supplement presents the latest evidence on quitlines from leading tobacco control and prevention researchers and practitioners," said Guest Co-editor Emily F. Gates, an assistant professor of Measurement, Evaluation, Statistics & Assessment at Boston College's Lynch School of Education and Human Development. "It showcases the efforts to customize services to reduce health disparities, recognizes the diverse tobacco product environment, and outlines ways to expand quitlines' reach through technological innovation, such as mobile apps and text messaging. Although compiled prior to the COVID-19 pandemic, it nonetheless reinforces the urgency and value of quitting tobacco, and the benefits of quitlines in facilitating the achievement of that critically important goal."

CDC Researcher Rebecca Glover-Kudon served as co-editor in coordination with a CDC working group and lead editors of the American Journal of Preventive Medicine.

Credit: 
Boston College

The impact of lockdown drives us to make poorer choices

Lockdown and other restrictions imposed to control the COVID-19 pandemic have had unseen negative effects on the cognitive capacity and mental health of the population. A study led by the UOC's research group Open Evidence, in collaboration with international universities and BDI Schlseinger Group Market Research, has gauged the impact of the measures taken during the first and second waves of the virus on citizens of three European Union countries. The study concludes that the shock produced by the situation has reduced people's cognitive capacity, leading them to take more risks, despite the risk of contagion, and make poorer choices, including a tendency to be less altruistic and the desire to punish others.

The study, published in the open access journal Scientific Reports, published by Nature, analyses the relationship between the negative impact of pandemic control measures and people's cognitive functioning and risk, time and social preferences.

The sample consisted of nearly 5,000 volunteers from Spain, Italy and the United Kingdom - three countries criticized for their poor management of the pandemic, where lockdown has had a greater impact on their populations than in other European states. The participants were asked to respond to questionnaires during the first and second waves of the pandemic.

In the first of the two questionnaires, the researchers collected data on levels of exposure to four types of impacts during lockdown: occupational, health, mental health, and stress. In the second, they measured the cognitive function of the volunteers, as well as a series of parameters related to risk, decision-making, altruism, and reciprocity, among others.

"We wanted to explore the impact of lockdown and other COVID-19-related restrictions on people's lives and how this affected their decision-making," explained Francisco Lupiáñez, professor of Information and Communication Sciences and member of Open Evidence.

The results of the study show that those who were more exposed to the consequences of the effects of lockdown also experienced more diminished cognitive capacity, made riskier decisions, and suffered reduced civic-mindedness.

"People's impaired decision-making abilities were impaired, and their reactions were not those we might have expected," said the researcher. "Instead of being more careful because they were in a pandemic, they were taking risks, because they couldn't take it any more." As for their relations with others, "they wanted, for example, those who did not wear masks or evaded restrictions to be punished, even though they themselves were more likely to make riskier choices".

According to Lupiáñez, "very difficult choices were made without taking into account the social cost involved. They only took into account a single, short-term perspective. And now we know that four out of ten people were at risk of suffering a mental health-related illness as a result of the shock produced by this pandemic. All this will have implications in the medium term".

Another of the effects identified by the authors of this paper is that, under the shock of the pandemic, people tended to want immediate benefits and made on-the-spot decisions, some of them momentous, such as deciding to move from the city to a rural setting. "These were decisions in which the cost-benefit assessment was highly conditioned by the pandemic. It seemed as if the world was coming to an end and people preferred to benefit today, immediately, without thinking about tomorrow," said Lupiáñez.

According to the authors, their conclusions have important implications in terms of public health. The current pandemic and the various mitigation strategies, such as lockdowns, have had significant detrimental consequences in terms of occupational and health impacts. It is important, they say, that these be taken into account in "designing better responses and communication campaigns for future pandemics".

Credit: 
Universitat Oberta de Catalunya (UOC)

A giant, sizzling planet may be orbiting the star Vega

Astronomers have discovered new hints of a giant, scorching-hot planet orbiting Vega, one of the brightest stars in the night sky.

The research, published this month in The Astronomical Journal, was led by University of Colorado Boulder student Spencer Hurt, an undergraduate in the Department of Astrophysical and Planetary Sciences.

It focuses on an iconic and relatively young star, Vega, which is part of the constellation Lyra and has a mass twice that of our own sun. This celestial body sits just 25 light-years, or about 150 trillion miles, from Earth--pretty close, astronomically speaking.

Scientists can also see Vega with telescopes even when it's light out, which makes it a prime candidate for research, said study coauthor Samuel Quinn.

"It's bright enough that you can observe it at twilight when other stars are getting washed out by sunlight," said Quinn, an astronomer at the Harvard and Smithsonian Center for Astrophysics (CfA).

Despite the star's fame, researchers have yet to find a single planet in orbit around Vega. That might be about to change: Drawing on a decade of observations from the ground, Hurt, Quinn and their colleagues unearthed a curious signal that could be the star's first-known world.

If the team's findings bear out, the alien planet would orbit so close to Vega that its years would last less than two-and-a-half Earth days. (Mercury, in contrast, takes 88 days to circle the sun). This candidate planet could also rank as the second hottest world known to science--with surface temperatures averaging a searing 5,390 degrees Fahrenheit.

Hurt said the group's research also helps to narrow down where other, exotic worlds might be hiding in Vega's neighborhood.

"This is a massive system, much larger than our own solar system," Hurt said. "There could be other planets throughout that system. It's just a matter of whether we can detect them."

Youthful energy

Quinn would like to try. Scientists have discovered more than 4,000 exoplanets, or planets beyond Earth's solar system, to date. Few of those, however, circle stars that are as bright or as close to Earth as Vega. That means that, if there are planets around the star, scientists could get a really detailed look at them.

"It would be really exciting to find a planet around Vega because it offers possibilities for future characterization in ways that planets around fainter stars wouldn't," Quinn said.

There's just one catch: Vega is what scientists call an A-type star, the name for objects that tend to be bigger, younger and much faster-spinning than our own sun. Vega, for example, rotates around its axis once every 16 hours--much faster than the sun with a rotational period that clocks in at 27 Earth days. Such a lightning-fast pace, Quinn said, can make it difficult for scientists to collect precise data on the star's motion and, by extension, any planets in orbit around it.

To take on that game of celestial hide-and-seek, he and colleagues pored through roughly 10 years of data on Vega collected by the Fred Lawrence Whipple Observatory in Arizona. In particular, the team was looking for a tell-tale signal of an alien planet--a slight jiggle in the star's velocity.

"If you have a planet around a star, it can tug on the star, causing it to wobble back and forth," Quinn said.

Hot and puffy

The search may have paid off, said Hurt, who began the study as a summer research fellow working for Quinn at the CfA. The team discovered a signal that indicates that Vega might host what astronomers call a "hot Neptune" or maybe a "hot Jupiter."

"It would be at least the size of Neptune, potentially as big as Jupiter and would be closer to Vega than Mercury is to the sun," Hurt said.

That close to Vega, he added, the candidate world might puff up like a balloon, and even iron would melt into gas in its atmosphere.

The researchers have a lot more work to do before they can definitively say that they've discovered this sizzling planet. Hurt noted that the easiest way to look for it might be to scan the stellar system directly to look for light emitted from the hot, bright planet.

For now, the student is excited to see his hard work reflected in the constellations: "Whenever I get to go outside and look at the night sky and see Vega, I say 'Hey, I know that star."

Credit: 
University of Colorado at Boulder

Study: Moral outrage is attractive among long-term relationship seekers

FAYETTEVILLE, Ark. - Moral outrage is an attractive behavior, particularly to people seeking long-term relationships, according to a new paper by researchers including a University of Arkansas psychologist.

The work indicates that people who displayed moral outrage were considered more benevolent and trustworthy than a control person not displaying outrage, and therefore more likely to possess other prosocial behaviors that would benefit a long-term relationship. There was a catch, however: Researchers found that people had to take action to address the moral wrong in question and not just talk about it to be more attractive to the opposite sex.

"I've done previous work where I've looked at how prosocial behavior actually makes individuals be seen as better long-term prospects," said Mitch Brown, psychology instructor and first author of the study published in the journal Emotion. "But I was interested in understanding how emotional displays could do the same thing, actually."

Brown and his colleagues conducted four studies with a total of 870 participants designed to investigate how displays of moral outrage were perceived in the context of mating. Participants were asked to rate the attractiveness of fictional dating profiles of people of the same and opposite sexes. The study focused on heterosexuals, and the same-sex questions were used to gauge perceptions of how moral outrage influenced perceptions of an individual as interest in mating. "This latter test has important implications for identifying likely sources of intrasexual competition that could interfere with one's own mating goals," the researchers wrote.

They found that both sexes viewed moral outrage as desirable for a long-term mate, but women were much more attracted than men possibly due to the prosocial attitudes of trustworthiness and benevolence it conveyed that could be seen as more valuable to women. "Women incur a substantially larger minimal cost in reproduction (e.g., nine-month gestation, lactation) compared with men (e.g., single instance of sperm provision), which necessitates employment of stringent mate selection criteria to offset these costs," the authors wrote.

They also found that the expression of moral outrage alone did not increase attractiveness, possibly because outrage without action could heighten perceptions of undesirable traits such as neuroticism and disagreeableness.

Credit: 
University of Arkansas

Can the digital advertising market achieve privacy without regulation?

Key Takeaways:

Machine learning offers more accurate targeting in mobile advertising.

Behavioral targeting is more effective than contextual targeting.

There is a possibility for self-regulation because too much behavioral targeting can reduce competition and hurt ad networks' revenues.

CATONSVILLE, MD, March 8, 2021 - It's a common assumption among marketers that if you can customize any form of marketing, particularly mobile advertising, you'll get better results. With this in mind, mobile marketing relies significantly on user tracking data as a cornerstone advertising strategy.

New research has looked into the value of user tracking data for targeting purposes and offered some insights about the privacy outcomes of such activities in a multisided mobile advertising market. This not only represents new thinking on marketing strategy, but could help mitigate certain societal concerns over privacy issues and the use of certain tracking data in mobile advertising.

The research study, "Targeting and Privacy in Mobile Advertising," is to be published in the March issue of the INFORMS journal Marketing Science. It is authored by Omid Rafieian of Cornell University and Hema Yoganarasimhan of the University of Washington.

The study found that a machine learning-based targeting approach improves the average click-through rate by more than 66.8% compared to simpler targeting models.

"The difference mainly stems from behavioral information as opposed to contextual information," said Rafieian. "What this means is that the machine-learning approach is able to learn user preferences from their past behavioral data, such as the ads they have seen and clicked on. Unlike traditional approaches, machine-learning methods do not put restrictive assumption on user behavior, and in turn, are able to identify more complex patterns in user preference."

"Once we established the effectiveness of our machine-learning approach, we turned to the privacy question: can we expect any stop on behavioral targeting and user tracking in this market?," said Yoganarasimhan. "What we found was that although behavioral targeting helps advertisers find better match with impressions, the ad network may want to protect consumer privacy and not allow very granular behavioral targeting for economic reasons. This is because too much targeting can result in softer competition between advertisers, where each advertiser cherry-picks narrow segments, thereby leading to lower revenues for ad networks."

The research used large-scale data from a leading in-app network of a country in Asia. Study authors created a machine-learning framework for targeting that uses both contextual and behavioral information.

They conducted a comprehensive comparison between the value of contextual and behavioral targeting from different players' viewpoints. The key insight from the paper was a misalignment between what ad networks and advertisers want: while advertisers demand more privacy-invasive targeting tools, ad networks have natural economic incentives to limit behavioral targeting to increase competition between advertisers. This hints at a future where the market can self-regulate and protect consumers' privacy.

Credit: 
Institute for Operations Research and the Management Sciences

Oncotarget: Sensitivity testing on ovarian cancer cells isolated from malignant ascites

image: In vitro drug sensitivity analysis of primary patient-derived tumor cells. Dose-response curves of the first-line chemotherapeutic agents carboplatin and paclitaxel on tumor cells isolated from ascites of three patients. Cells were seeded in microtiter plates and allowed to adapt for 24 hours before drug was added. Effect on cell growth was determined after 120 hours drug exposure by measuring intracellular ATP content as an indirect readout of cell number. The horizontal green line corresponds to the number of cells before addition of drug.

Image: 
Correspondence to - Anne M. van Altena - Anne.vanAltena@radboudumc.nl

Oncotarget published "Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascites" which reported that the authors aim is to determine the feasibility of cell proliferation assays of tumor cells isolated from malignant ascites to predict in vitro chemotherapy sensitivity, and to correlate these results with clinical outcome.

Cell samples were enriched for tumor cells and EOC origin was confirmed by intracellular staining of CK7, surface staining of CA125 and EpCAM, and HE4 gene expression.

In vitro sensitivity to chemotherapy was determined in cell proliferation assays using intracellular ATP content as an indirect measure of cell number.

In twelve of the fourteen remaining cases in vitro drug sensitivity and clinical outcome corresponded, while in two samples there was no correspondence.

Larger observational studies are required to confirm the correlation between the in vitro sensitivity and clinical outcome.

Dr. Anne M. van Altena from The Radboud University Medical Center said, "Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy worldwide."

Standard first-line treatment for advanced EOC consists of a combination of a debulking surgery and chemotherapy, with paclitaxel and a platinum-based compound administered either intravenously or intraperitoneally.

There is a need for more tools and assays to predict the clinical response to chemotherapy in EOC patients.

Konecny and co-workers reported a significant decrease in progression-free and overall survival of patients tested to be resistant in vitro using ATP tumor chemosensitivity assays performed on tumor cells isolated from biopsies.

A more personalized, tumor-specific treatment for EOC patients would be of great value to improve therapeutic decision-making and clinical outcome.

The aim of this Oncotarget study is to determine whether tumor cells isolated from ascites of EOC patients can be used to determine chemotherapy sensitivity by using in vitro proliferation assays.

The aim of this Oncotarget study is to determine whether tumor cells isolated from ascites of EOC patients can be used to determine chemotherapy sensitivity by using in vitro proliferation assays.

The van Altena Research Team concluded in their Oncotarget Research Paper, "our study shows the feasibility of assessing in vitro chemotherapy sensitivity on tumor cells isolated from ascites. A larger, prospective study, which takes into account the insights that were gained in this pilot study, is ongoing and will be reported in due course."

Sign up for free Altmetric alerts about this article

DOI - https://doi.org/10.18632/oncotarget.27827

Full text - https://www.oncotarget.com/article/27827/text/

Correspondence to - Anne M. van Altena - Anne.vanAltena@radboudumc.nl

Keywords -
ovarian cancer,
chemotherapy sensitivity,
prediction,
ascites,
proliferation assays

About Oncotarget

Oncotarget is a weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit http://www.ImpactJournals.com or connect with @ImpactJrnls

Journal

Oncotarget

DOI

10.18632/oncotarget.27827

Credit: 
Impact Journals LLC

Oncotarget: High-fat ovariectomized mice susceptible to accelerated tumor growth

image: Differential tumor-associated macrophage phenotype in female and OVX mice.

Image: 
Correspondence to - Angela Murphy - Angela.Murphy@uscmed.sc.edu

Oncotarget published "High-fat diet-fed ovariectomized mice are susceptible to accelerated subcutaneous tumor growth potentially through adipose tissue inflammation, local insulin-like growth factor release, and tumor associated macrophages" which reported that the association between obesity and colorectal cancer (CRC) risk has been well established. This relationship appears to be more significant in men than in women, which may be attributable to sex hormones - controlled animal studies to substantiate these claims and the mechanisms involved are lacking. MC38 murine colon adenocarcinoma cells were injected subcutaneously into high-fat diet fed male, female and ovariectomized female C57BL/6 mice.

HFD OVX mice exhibited the most significant tumor growth compared to HFD male and female mice and this was associated with increased subcutaneous adipose tissue.

Further, the subcutaneous adipose tissue depots within HFD OVX mice exhibited more severe macrophage associated inflammation compared to female, but not male mice.

Conditioned media from subcutaneous adipose tissue of HFD OVX contained higher IGF-1 levels compared to male, but not female mice.

Finally, HFD OVX mice had increased M2-like gene expression in their tumor-associated macrophages compared to female mice.

Dr. Angela Murphy from The University of South Carolina said, "There is convincing evidence that excess body weight is associated with increased risk for late onset (> 50 years of age) colorectal cancer (CRC)."

There is convincing evidence that excess body weight is associated with increased risk for late onset (> 50 years of age) colorectal cancer (CRC)

Taken together, the current literature suggests that:

sex disparities are evident in obesity-enhanced CRC, and
hormonal status likely plays a role in CRC risk in women

These perturbations have been associated with CRC risk and are likely biological factors that link obesity to CRC risk.

For instance, the homeostasis model of risk assessment-insulin resistance has been reported to be associated with risk for CRC.

As hormone status is an influential risk factor for both obesity and CRC, the Oncotarget authors also sought to examine the effect of ovarian hormone deficiency on obesity-enhanced CRC.

Overall, this study provides insight into the contributions of hormonal status, fat distribution, and local versus systemic effects of obesity on CRC risk.

The Murphy Research Team concluded in their Oncotarget Research Paper, "our study confirms that established obesity following 20–21 weeks of high-fat-diet feedings enhanced the growth of subcutaneously implanted MC38 tumors, but this appears to be largely due to the increase in tumorigenesis in the OVX mice. We established that diet induced obesity and associated insulin resistance manifest differently in male, female, and OVX mice. Although we were unable to completely replicate epidemiological data, we report that obese OVX mice are most vulnerable to accelerated subcutaneous tumor growth in the MC38 model. Our data suggest several potential mechanisms including increased local adiposity, increased local inflammation and IGF-1, and polarization of macrophages to an M2 phenotype, providing insight into this obesity enhanced tumor growth in OVX mice."

Sign up for free Altmetric alerts about this article

DOI - https://doi.org/10.18632/oncotarget.27832

Full text - https://www.oncotarget.com/article/27832/text/

Correspondence to - Angela Murphy - Angela.Murphy@uscmed.sc.edu

Keywords -
colorectal cancer,
obesity,
metabolism,
macrophage,
inflammation

About Oncotarget

Oncotarget is a weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit http://www.ImpactJournals.com or connect with @ImpactJrnls

Journal

Oncotarget

DOI

10.18632/oncotarget.27832

Credit: 
Impact Journals LLC

3D printing materials for printing aorta model to study optimal CT scanning protocols

Personalised 3D printed models created from cardiac imaging data, mainly from cardiac CT images have been increasingly used in cardiovascular disease, primarily in the preoperative planning and simulation of complex surgical procedures, as well as medical education. 3D printed models are proved to be highly accurate in replicating normal anatomy and cardiac pathology with reported differences less than 0.5 mm between 3D printed models and original sources images. Further to these applications, a new research direction of utilising 3D printed models is to study the optimal CT scanning protocols in cardiovascular disease with the aim of reducing radiation dose while preserving diagnostic image quality. To achieve this goal, an appropriate printing material is essential to ensure that the printed models possess elasticity and flexibility similar to normal tissue properties.

Zhonghua Sun, a John Curtin Distinguished Professor and medical imaging researcher from Curtin University, Australia has been in search of suitable 3D printing materials to print realistic models, and more importantly, to print cardiovascular models with similar tissue properties to replicate heart and aortic arteries. Prof. Sun's research interests lie in 3D image visualization and diagnosis; 3D printing, virtual reality and artificial intelligence in medical applications, specifically in the cardiovascular disease. In his recent work, published in Current Medical Imaging, Prof. Sun and his team presents research findings for printing the aorta models with printing materials having similar CT attenuation to that of normal aortic wall on both pre- and post-contrast CT scans. This study further advances the current applications of 3D printing in cardiovascular disease to another level by presenting evidence that 3D printed personalised aorta models can be used to study optimal CT protocols, in addition to the value that 3D printed aorta models serve as a useful tool for pre-surgical planning and simulation of endovascular repair of aortic disease.

In his latest article, Prof Sun and his team reported findings on how the identified materials can be used to print realistic aorta models. They first created a 25-mm long type B aortic dissection model from CT images, then printed 4 models with use of two materials, namely Agilus from Stratasys and Visijet CE-NT from 3D Systems. These materials are soft and can be mixed with another material such as photopolymer resin to create a range of products with different elastic properties. These 4 aortic models consisted of two Agilus models printed with A40 and A50, representing two different degrees of hardness, another two Visijet models printed with Visijet CE-NT with different hardness, A30 and A70. The Visijet CE-NT A30 has a tensile strength between 0.2 and 0.4 which is close to the aging arteries, while Agilus A40 and A50 have a tensile strength of 0.5 to 1.5. The 4 aorta models were scanned on a 192-slice CT scanner with the standard aorta CTA protocol, and the scans were performed with and without use of contrast medium to measure CT attenuation at true lumen, false lumen, intimal flap and two junction areas between the true and false lumens. Results showed that Agilus models had higher CT attenuation than Visijet CE-NT models on non-contrast CT images, with Agilus A50 having an average CT attenuation similar to that of original CT images. On contrast images, only Visijet CE-NT A30 produced CT attenuation similar to that of original images, while the remaining models printed with other materials resulted in significantly higher CT attenuation than that of original images. This study shows that Visijet CE-NT A30 is considered an appropriate material to print aortic dissection model due to its similar elasticity to the normal aorta.

Aorta CT angiography (CTA) is currently the reference method in preoperative assessment of aortic aneurysm and dissection. Further, CTA is commonly used to follow-up patients treated with endovascular stent grafts. Therefore, regular CTA follow-ups of these patients at 3, 6 and 12 months, yearly thereafter contribute to cumulative radiation dose, which raises serious concerns due to radiation-induced malignancy. Dose optimization is clinically important to these patients receiving multiple CT scans. "3D printed aortic models with Visijet CE-NT material give the appearance of translucent light yellow allowing its use for education purpose, in addition to its reported value in guiding complex aortic surgery or endovascular aortic repair," says Prof. Sun. He also added "printing aortic dissection models is very challenging compared to other cardiovascular models due to very thin membranous structure of the intimal flap." The CTA images used in this study represented nice anatomical structures including intimal flap which were segmented and printed without any difficulty. This confirms the importance of quality of source images to guarantee printing high-quality models.

Prof. Sun's team is continuing to work on printing more anatomical structures including ribs, thoracic vertebrae, soft tissues, lungs and heart which allows for simulation of more realistic environment. "The phantom should be improved to mimic the in vivo circumstance and this allows for investigation of optimal aorta CT scanning protocols for detection of aortic dissection," says Prof. Sun.

Credit: 
Bentham Science Publishers